Systematic review with meta‐analysis: <i>Saccharomyces boulardii</i> supplementation and eradication of <i>Helicobacter pylori</i> infection

Szajewska, Hania; Horvath, Andrea; Kołodziej, Maciej

doi:10.1111/apt.13214

Cited by 109 publications

(81 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2010, a first meta-analysis showed that S. boulardii reduced the risk or overall adverse events (RR 0.46, 95% CI 0.3 to 0.7) 414. In 2015, the same group reported an updated meta-analysis, with comparable results: S. boulardii decreased the risk and overall adverse effects (RR 0.44, 95% CI 0.31 to 0.64) 415. Encouraging data on other probiotics, such as Bacillus clausii , have emerged from double-blind RCTs 416…”

Section: Working Group 5: H Pylori and The Gastric Microbiotamentioning

confidence: 99%

See 1 more Smart Citation

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

Malfertheiner

Mégraud

O’Moráin

et al. 2016

Gut

2,444

3,052

View full text Add to dashboard Cite

Section: Working Group 5: H Pylori and The Gastric Microbiotamentioning

confidence: 99%

“…In two meta-analyses, S. boulardii was shown to increase the H. pylori eradication rate, with, respectively, RRs of 1.13 (95% CI 1.05 to 1.21)414 and 1.11 (95% CI 1.06 to 1.17) 415…”

Section: Working Group 5: H Pylori and The Gastric Microbiotamentioning

confidence: 99%

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

Malfertheiner

Mégraud

O’Moráin

et al. 2016

Gut

2,444

3,052

View full text Add to dashboard Cite

“…However, data in children were limited (eradication rate: two RCTs, n=330, RR 1.13, 95% CI 1.03 to 1.25) 33. Of note, while in both analyses the addition of probiotics to standard triple therapy significantly increased the eradication rate, it was still below the desired level (≥90%) of success.…”

Section: Clinical Effects Of Probioticsmentioning

confidence: 92%

What are the indications for using probiotics in children?

Szajewska

2015

Arch Dis Child

View full text Add to dashboard Cite

The health benefits of probiotics have been the subject of extensive research. Still, some questions are being repeatedly asked: should one use or not use probiotics? If yes, how and when should probiotics be used? The purpose of this review is to summarise current evidence on specific probiotics' efficacy and safety to help healthcare professionals make evidence-based decisions on the indications for using specific probiotic strains or combinations in children. To identify relevant data, searches of MEDLINE and the Cochrane Library databases were performed in July 2015 to locate randomised controlled trials or their meta-analyses published in the last five years. The MEDLINE database also was searched for evidence-based clinical practice guidelines, developed by scientific societies. Considering that probiotics have strain-specific effects, the main focus was on data on individual probiotic strains, not on probiotics in general.

show abstract

“…Diarrhea, nausea, vomiting, bloating, and abdominal pain may occur in the process of H. pylori eradication because of the antibiotics used in the regimens. Numerous meta-analyses have implicated the importance of Pbs (mainly Lactobacillus or Saccharomyces boulardii or Bacillus clausii ) in improving H. pylori -related side effects (Nista et al, 2004; Tong et al, 2007; Zou et al, 2009; Szajewska et al, 2010, 2015; Wang et al, 2013; Dang et al, 2014; Zhang M. M. et al, 2015; McFarland et al, 2016). One meta-analysis (Zou et al, 2009) proposed that certain types of multi-strain probiotic mixtures might reduce adverse events and antibiotic-associated diarrhea; the results showed that five mixtures ( L. acidophilus/B.…”

Section: Treatmentmentioning

confidence: 99%

Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance

Zhu

Lü

2017

Front. Cell. Infect. Microbiol.

130

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a common gastrointestinal bacterial strain closely associated with the incidence of chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. A current research and clinical challenge is the increased rate of antibiotic resistance in H. pylori, which has led to a decreased H. pylori eradication rate. In this article, we review recent H. pylori infection and reinfection rates and H. pylori resistance to antibiotics, and we discuss the pertinent treatments. A PubMed literature search was performed using the following keywords: Helicobacter pylori, infection, reinfection, antibiotic resistance, bismuth, proton pump inhibitors, vonoprazan, susceptibility, quintuple therapy, dual therapy, and probiotic. The prevalence of H. pylori has remained high in some areas despite the decreasing trend of H. pylori prevalence observed over time. Additionally, the H. pylori reinfection rate has varied in different countries due to socioeconomic and hygienic conditions. Helicobacter pylori monoresistance to clarithromycin, metronidazole or levofloxacin was common in most countries. However, the prevalence of amoxicillin and tetracycline resistance has remained low. Because H. pylori infection and reinfection present serious challenges and because H. pylori resistance to clarithromycin, metronidazole or levofloxacin remains high in most countries, the selection of an efficient regimen to eradicate H. pylori is critical. Currently, bismuth-containing quadruple therapies still achieve high eradication rates. Moreover, susceptibility-based therapies are alternatives because they may avoid the use of unnecessary antibiotics. Novel regimens, e.g., vonoprazan-containing triple therapies, quintuple therapies, high-dose dual therapies, and standard triple therapies with probiotics, require further studies concerning their efficiency and safety for treating H. pylori.

show abstract

Systematic review with meta‐analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection

Abstract: SUMMARY BackgroundUnsatisfactory Helicobacter pylori eradication rates and therapy-associated side effects remain a problem.

Cited by 109 publications

References 27 publications

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

What are the indications for using probiotics in children?

Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance

Contact Info

Product

Resources

About